secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001213900-23-063806
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar corrects REZPEG Phase 1b data; atopic dermatitis EASI-75 rate now 41% vs 29% reported by Lilly
--------------------------------------------------------------------------------

- Highest REZPEG dose (24 µg/kg) in atopic dermatitis achieved 83% mean EASI improvement (p=0.002 vs placebo).
- EASI-75 response rate corrected from previously reported 29% to 41% (NRI) and 58% as observed.
- Psoriasis data also corrected: PASI-50 rate rose to 32% (NRI) and PASI-75 to 21% (NRI); p-values remained non-significant.
- Errors discovered after Lilly returned rights; independent statistical firm reanalyzed raw data.
- Nektar plans to start Phase 2b study in moderate-to-severe atopic dermatitis in October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023063806/0001213900-23-063806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023063806/ea182964-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-063806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer